Matricaria Recutita Flowering Top

Dosage for Matricaria Recutita Flowering Top is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Diagnostic Testing

• Percutaneous (Prick/Puncture): Usually, a single drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a prick through the drop. Results are read after 15–20 minutes.
• Intradermal: If the prick test is negative but suspicion remains high, a dose of 0.02 mL to 0.05 mL of a much more dilute solution (e.g., 1:1000 w/v) may be injected into the skin.

Immunotherapy (Hyposensitization)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are given 1–2 times per week, with the dose increasing gradually by 25% to 50% at each visit, provided no significant local reactions occur.
• Maintenance Phase: Once the 'maintenance dose' is reached (the highest dose tolerated without systemic reactions), the interval between injections is increased to every 2–4 weeks. This phase may last for 3 to 5 years.

Matricaria Recutita Flowering Top extract can be used in children, but extreme caution is required. Pediatric dosing follows the same escalation principles as adult dosing, but starting doses may be even more conservative. Children under the age of 5 may have difficulty communicating the early symptoms of a systemic reaction, and therefore, the risks and benefits must be carefully weighed by the physician.

Renal Impairment

No specific dose adjustments are provided in the manufacturer's labeling for renal impairment. However, clinicians should monitor patients closely, as overall health status can affect the body's ability to recover from a potential systemic allergic reaction.

Hepatic Impairment

There are no known requirements for dosage adjustment in patients with liver disease, as the extract is primarily metabolized by proteases rather than hepatic CYP450 enzymes.

Elderly Patients

Elderly patients may have a higher risk of complications if a systemic reaction occurs, particularly if they have underlying cardiovascular disease. Dosing should be approached with caution, and the use of beta-blockers must be evaluated, as they can complicate the treatment of anaphylaxis.

This medication is NEVER for self-administration at home. It must be administered by a healthcare professional in a clinical setting equipped to treat anaphylaxis.

• Administration: Subcutaneous injections should be given in the outer aspect of the upper arm. The site should not be massaged after injection.
• Observation: Patients MUST remain in the clinic for at least 30 minutes following any injection to monitor for signs of a systemic reaction.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

In immunotherapy, consistency is vital. If a dose is missed:

• Short Delay (1-2 weeks): The previous dose may be repeated.
• Long Delay (over 4 weeks): The dose may need to be significantly reduced to ensure safety, and the build-up process may need to be partially restarted. Talk to your doctor immediately if you miss an appointment.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. Signs include:

• Rapid onset of hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Sudden drop in blood pressure (fainting/dizziness)

In the event of an overdose/systemic reaction, epinephrine is the first-line treatment. Emergency medical services must be contacted immediately if symptoms occur outside the clinic.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients undergoing testing or treatment with Matricaria Recutita Flowering Top will experience local reactions. These are generally expected and indicate that the extract is biologically active.

• Injection Site Redness (Erythema): A red area around the site of the prick or injection. This typically appears within minutes and may last for several hours.
• Itching (Pruritus): Intense itching at the site of administration is very common.
• Wheal Formation: A raised, pale bump at the test site, similar to a mosquito bite. In diagnostic testing, a wheal larger than 3mm is often considered a positive result.
• Local Swelling: Some swelling at the injection site is common in immunotherapy. If the swelling is smaller than the size of a half-dollar, it is usually considered a normal local reaction.

• Delayed Local Reactions: Swelling or redness that appears 6 to 24 hours after the injection. While uncomfortable, these are usually not dangerous but should be reported to the doctor before the next dose.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy injection.
• Mild Nasal Congestion: A slight increase in 'hay fever' symptoms shortly after administration.

• Generalized Hives: Itching and hives appearing on parts of the body far away from the injection site.
• Persistent Granuloma: A small, hard lump under the skin at the injection site that may take weeks or months to resolve.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (usually in the armpit).

> Warning: Stop taking Matricaria Recutita Flowering Top and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or a feeling of 'air hunger.' This indicates a systemic constriction of the airways.
• Angioedema: Significant swelling of the lips, tongue, or face, which can lead to airway obstruction.
• Hypotension: A sudden, dangerous drop in blood pressure, often characterized by extreme dizziness, pallor, or loss of consciousness.
• Tachycardia: A rapid or pounding heartbeat as the body attempts to compensate for allergic shock.
• Uterine Contractions: In rare cases, systemic allergic reactions can trigger uterine cramping in pregnant women.

The long-term use of Matricaria Recutita Flowering Top in immunotherapy is generally considered safe when administered correctly. There is no evidence that long-term use causes organ damage, cancer, or autoimmune diseases. The primary long-term risk is the cumulative risk of a systemic reaction over the years of treatment. Some patients may develop a persistent sensitivity at the injection site, making further injections difficult.

Matricaria Recutita Flowering Top, like all allergenic extracts, carries a significant risk of severe systemic reactions. While there is no specific 'Black Box' text unique to chamomile, the FDA requires all allergenic extracts to carry warnings regarding Anaphylaxis. The warning emphasizes that these products should only be administered by clinicians prepared to manage life-threatening allergic reactions and that patients with unstable asthma are at a significantly higher risk of fatality.

Report any unusual symptoms to your healthcare provider.

Matricaria Recutita Flowering Top is a potent biological agent. Its use is restricted to diagnostic and therapeutic procedures under the direct supervision of a physician trained in allergy and immunology. Patients must be informed that while immunotherapy can reduce allergy symptoms, it also carries the inherent risk of triggering the very symptoms it aims to treat.

No FDA black box warnings for Matricaria Recutita Flowering Top specifically, but it falls under the general FDA mandate for allergenic extracts which states:

• Risk of Anaphylaxis: This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• Setting: Must be administered in a facility with personnel and equipment capable of managing anaphylactic shock.
• Observation: Patients must be observed for at least 30 minutes post-injection.
• Asthma Warning: Patients with unstable or severe asthma are at increased risk for severe reactions and death.

• Allergic Reactions / Anaphylaxis Risk: The most significant risk is a systemic Type I hypersensitivity reaction. Patients should be screened for any history of severe reactions to chamomile-containing products (including teas and lotions) before testing begins.
• Asthma Status: Immunotherapy should not be administered if the patient is experiencing an acute asthma flare-up. The patient's FEV1 (forced expiratory volume) should be stable before receiving an injection.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be less able to tolerate the physiological stress of a systemic reaction or the effects of epinephrine used to treat such a reaction.
• Infection: Injections should be deferred if the patient has an acute infection or fever, as this can lower the threshold for a systemic allergic reaction.

• Pre-Injection Assessment: Before every dose, the healthcare provider must ask about any 'late' reactions from the previous dose and assess the patient's current respiratory status.
• Observation Period: A strict 30-minute wait time in the clinic is mandatory after every injection.
• Lung Function: For asthmatic patients, peak flow monitoring or spirometry may be required before administration.

While the extract itself does not cause sedation, a systemic reaction or the administration of epinephrine can cause dizziness, tremors, and impaired coordination. Patients should ensure they feel completely normal before driving away from the clinic after their observation period.

Alcohol consumption should be avoided on the day of an immunotherapy injection. Alcohol can increase peripheral blood flow (vasodilation), which may theoretically increase the rate of allergen absorption from the injection site and increase the risk of a systemic reaction.

Immunotherapy can be discontinued if the patient experiences a life-threatening systemic reaction. If a patient decides to stop treatment for other reasons, there is no 'withdrawal' syndrome, but the allergic symptoms that were being managed are likely to return over time. Tapering is not required for discontinuation.

> Important: Discuss all your medical conditions with your healthcare provider before starting Matricaria Recutita Flowering Top.

There are no absolute drug-drug contraindications that prevent the use of Matricaria Recutita Flowering Top, but certain medications make its use significantly more dangerous.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These are often considered a relative contraindication. If a patient on a beta-blocker has an anaphylactic reaction to the extract, the beta-blocker may prevent epinephrine from working effectively. This can lead to 'epinephrine-resistant' anaphylaxis, which is often fatal.

• ACE Inhibitors (e.g., Lisinopril): Some evidence suggests that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions during immunotherapy.
• Tricyclic Antidepressants (TCAs) and MAOIs: These medications can potentiate the effect of epinephrine. If epinephrine must be used to treat a reaction to the extract, the patient may experience a dangerous spike in blood pressure.

• Antihistamines (e.g., Loratadine, Cetirizine): These medications must be stopped 3 to 7 days before diagnostic skin testing. Antihistamines block the H1 receptors in the skin, which prevents the 'wheal and flare' reaction from occurring, leading to a false-negative result. They do not need to be stopped for immunotherapy, and in fact, are sometimes used to manage local reactions.
• Topical Steroids: Applying steroid creams to the test site (the back or arm) can suppress the skin's immune response and should be avoided for several days before testing.

• Chamomile Tea/Food: Patients undergoing immunotherapy for Matricaria Recutita should be cautious when consuming chamomile tea or foods containing chamomile, as this adds to the total 'allergen load' in their system and may increase the risk of a reaction on the day of their injection.
• Cross-Reactive Foods: Patients allergic to chamomile may also react to celery, honey, or sunflower seeds. These should be consumed with caution.

• Asteraceae Supplements: Supplements containing Echinacea, Feverfew, or Milk Thistle may contain proteins similar to those in Matricaria Recutita. Using these concurrently may increase the risk of an allergic response.

Matricaria Recutita Flowering Top does not typically interfere with standard blood chemistry or hematology tests. However, it will directly interfere with:

• Skin Prick Tests: As mentioned, the presence of the extract in the skin is the test itself.
• In Vitro Allergy Tests (sIgE): Immunotherapy will cause a rise in IgG4 levels and a potential initial rise followed by a long-term fall in IgE levels, which is the intended clinical outcome but must be interpreted correctly by the lab.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Matricaria Recutita Flowering Top must NEVER be used in the following circumstances:

• Severe, Unstable Asthma: Patients whose asthma is not well-controlled are at an extremely high risk of a fatal respiratory arrest if they experience a systemic reaction to the extract. According to clinical guidelines, an FEV1 persistently below 70% of predicted is generally an absolute contraindication for starting immunotherapy.
• Recent Myocardial Infarction: Patients who have had a heart attack within the last 3-6 months should not undergo testing or immunotherapy, as their heart cannot handle the stress of a potential anaphylactic event.
• History of Severe Anaphylaxis to this Extract: If a patient has previously had a life-threatening reaction to a very small dose of Matricaria Recutita extract, the risks of continuing treatment usually outweigh the benefits.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen conditions like Lupus or Rheumatoid Arthritis, though data is limited.
• Malignancy: Patients undergoing active chemotherapy or with advanced cancer are generally not candidates for immunotherapy.
• Beta-Blocker Therapy: As discussed, the risk of epinephrine resistance makes this a significant safety concern.

Patients with known severe allergies to the following substances should be approached with extreme caution, as they are likely to be cross-sensitive to Matricaria Recutita:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Daisies
• Arnica

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Matricaria Recutita Flowering Top.

Matricaria Recutita Flowering Top is generally classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.

• Initiation: Clinical guidelines strongly advise AGAINST starting immunotherapy during pregnancy. The risk of a systemic reaction (anaphylaxis) can cause fetal hypoxia (lack of oxygen) and potentially lead to miscarriage or preterm labor.
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the physician may choose to continue the treatment at the same or a slightly reduced dose, as the risk of a reaction is lower once maintenance is reached.

It is not known whether the allergenic components of Matricaria Recutita Flowering Top are excreted in human milk. However, because these are large proteins and the amount administered is small, the risk to a nursing infant is considered very low. The primary concern remains the mother's safety and the potential for a systemic reaction.

Allergenic extracts are used in children, often with great success in preventing the 'allergic march' (the progression from hay fever to asthma). However, children under 5 years of age are at a higher risk because they cannot always describe the 'feeling of impending doom' or itchy throat that signals the start of anaphylaxis. Pediatric use must be supervised by a specialist.

In patients over 65, the decision to use Matricaria Recutita Flowering Top must consider the patient's overall cardiovascular health. The elderly are more likely to be taking medications like beta-blockers or ACE inhibitors, and they have less physiological reserve to survive a severe systemic reaction. Skin reactivity also tends to decrease with age, which may lead to less reliable skin test results.

There are no specific guidelines for renal impairment. Since the extract consists of proteins that are naturally degraded, kidney function does not typically impact the dosing of allergenic extracts. However, severe renal disease may affect a patient's ability to tolerate emergency medications like epinephrine.

Liver disease does not affect the pharmacokinetics of Matricaria Recutita extract. No dose adjustments are required for patients with hepatic impairment, provided they are otherwise stable.

> Important: Special populations require individualized medical assessment.

Matricaria Recutita Flowering Top functions as an immunomodulator. In diagnostic use, it acts as an antigen that binds to allergen-specific IgE antibodies on the surface of cutaneous mast cells. This binding causes the IgE receptors (FcεRI) to aggregate, triggering an intracellular signaling cascade that results in the release of pre-formed mediators like histamine.

In therapeutic use (immunotherapy), the repeated administration of the extract induces a shift from a Th2-dominated immune response (which produces IgE) to a Th1-dominated or regulatory T-cell response. This leads to the production of IgG4 'blocking' antibodies. These IgG4 antibodies compete with IgE for the allergen binding sites, effectively preventing the allergen from reaching the mast cells and causing a reaction.

• Onset of Action (Diagnostic): 15 to 20 minutes for a skin wheal to appear.
• Onset of Action (Therapeutic): 6 to 12 months of consistent injections are usually required before a significant reduction in clinical symptoms is noted.
• Duration of Effect: Diagnostic skin reactivity can last for hours. Therapeutic effects can last for several years after the completion of a 3-to-5-year course of immunotherapy.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local administration) |

| Protein Binding | High (to IgE and IgG antibodies) |

| Half-life | Variable (Proteins degraded within hours/days) |

| Tmax | 15-30 mins (Systemic absorption post-SCIT) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (Metabolites) |

• Composition: A complex mixture of proteins (including the allergen Mat r 1), flavonoids (apigenin), and essential oils (chamazulene, bisabolol).
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for the primary allergenic proteins.
• Solubility: Soluble in aqueous solutions and glycerinated saline.

Matricaria Recutita Flowering Top is classified as a Non-Standardized Plant Allergenic Extract. It is related to other extracts in the Asteraceae family, such as Ambrosia artemisiifolia (Ragweed) and Artemisia vulgaris (Mugwort).